Edgewise Therapeutics (EWTX) Other Non-Current Liabilities (2021 - 2022)

Edgewise Therapeutics (EWTX) posted Other Non-Current Liabilities of $192000.0 for Q2 2022, up 2.67% sequentially from $187000.0 in Q1 2022.

Edgewise Therapeutics (EWTX) Other Non-Current Liabilities (2021 - 2022) Analysis & Trends

Edgewise Therapeutics has reported Other Non-Current Liabilities for 2 years, with the latest figure at $192000.0 in Q2 2022.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $192000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $192000.0 (changed N/A YoY) and the FY2021 annual result came in at $329000.0, changed N/A from the prior year.
Other Non-Current Liabilities advanced to $192000.0 in Q2 2022 per EWTX's latest filing, from $187000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $329000.0 in Q4 2021 and troughed at $187000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Edgewise Therapeutics	4.76 Bn	4.76 Bn	-

Download Data